Paroxetine: uses, dosing, side effects & brands
Paroxetine is a serotonin reuptake inhibitor sold in the U.S. under 6 brand and generic names, for feeding and eating disorders, depressive disorder and obsessive-compulsive disorder. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Drug class
- Serotonin Reuptake Inhibitor
- Treats (across its forms)
- Feeding and Eating Disorders, Depressive Disorder and Obsessive-Compulsive Disorder
- Available as
- Capsule · Suspension · Tablet, extended release · Tablet
- Sold as
- 6 products — Paroxetine Mesylate, Paroxetine Hydrochloride and Paxil, and others
- Prescription?
- Prescription only
- Generic available?
- Yes
- Half-life
- about 21 hours on average (the label reports a mean of approximately 21 hours, with 32% variability between people)
- What the pharmacy pays
- about $3 for a 30-count supply — not your price
- Boxed warning
- Boxed warning
Get treated for Paroxetine conditions online
Licensed online providers — consult & get prescribed if eligible.
Advertising disclosure: We may earn a commission, at no extra cost to you. This never affects our ratings. Details
How Brisdelle is dosed
From the FDA label for Brisdelle (application NDA204516). Other paroxetine products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
The recommended dosage of paroxetine capsules is 7.5 mg once daily, at bedtime (2.1) 2.1 Dosage Information The recommended dosage of paroxetine capsules for the treatment of moderate to severe VMS is 7.5 mg once daily, at bedtime, with or without food. 2.2 Use of Paroxetine Capsules Before or After a Monoamine Oxidase Inhibitor (MAOI) Wait at least 14 days after discontinuation of an MAOI before initiating therapy with paroxetine capsules. Conversely, allow at least 14 days after stopping paroxetine capsules before starting an MAOI [see Contraindications (4.1), Warnings and Precautions (5.2) and Drug Interactions (7.3)] .
Everything below is the FDA label for Brisdelle (capsule). Paroxetine is also sold as suspension, tablet, extended release and tablet, and those are different medicines to take — follow the label for the one you were prescribed.
Brisdelle side effects
The following serious adverse reactions are discussed elsewhere in labeling: • Suicidality [see Warnings and Precautions (5.1)] • Serotonin syndrome [see Warnings and Precautions (5.2)] • Abnormal bleeding [see Warnings and Precautions (5.4)] • Angle-Closure Glaucoma [see Warnings and Precautions (5.5)] • Hyponatremia [see Warnings and Precautions (5.6)] • Bone Fracture [see Warnings and Precautions (5.7)] • Mania/Hypomania [see Warnings and Precautions (5.8)] • Seizure [see Warnings and Precautions (5.9)] • Akathisia [see Warnings and Precautions (5.10)] • The most common adverse reactions (≥ 2%) reported in clinical trials were: headache, fatigue, and nausea/vomiting ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Padagis at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot directly be compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below reflect exposure to paroxetine capsules in the one 8-week Phase 2 randomized, placebo-controlled trial and the two Phase 3 randomized, placebo-controlled, 12-week and 24-week trials for the treatment of moderate to severe VMS [see Clinical Studies (14)] . In these…
Who shouldn’t take Brisdelle
Concurrent use with monoamine oxidase inhibitors (MAOI) or use within 14 days of MAOI use ( 2.2 , 4.1 , 5.2 , 7.3 ) • Use with thioridazine ( 4.2 , 7.1 ) • Use with pimozide ( 4.3 , 7.1 ) • Hypersensitivity to any ingredient in paroxetine capsules ( 4.4 ) • Pregnancy ( 4.5 , 8.1 ) 4.1 Monoamine Oxidase Inhibitors Concomitant use of an MAOI with paroxetine capsules or within 14 days of stopping treatment with paroxetine capsules is contraindicated because of an increased risk of serotonin syndrome. The use of paroxetine capsules within 14 days of stopping an MAOI is also contraindicated [see Dosage and Administration (2.2), Warnings and Precautions (5.2) and Drug Interactions (7.3)] . Starting paroxetine capsules in a patient who is being treated with linezolid or intravenous methylene blue, both of which inhibit monoamine oxidase, is also contraindicated because of an increased risk of serotonin syndrome [see Dosage and Administration (2.2), Warnings and Precautions (5.2) and Drug Interactions (7.3)] . 4.2 Thioridazine Concomitant use of paroxetine capsules with thioridazine is contraindicated, because thioridazine prolongs the QT interval, and paroxetine can increase thioridazine levels [see Drug Interactions (7.1)] . 4.3 Pimozide Concomitant use of paroxetine capsules with pimozide is contraindicated because pimozide prolongs the QT interval, and paroxetine increases pimozide levels [see Drug Interactions (7.1)] . 4.4 Hypersensitivity to any Ingredient in Paroxetine Capsules Paroxetine capsules are contraindicated in patients with a history of hypersensitivity to paroxetine or any of the other ingredients in paroxetine capsules. 4.5 Pregnancy Menopausal VMS does not occur during pregnancy and paroxetine capsules may cause fetal harm [see Use in Specific Populations (8.1)].
Brisdelle drug interactions
No drug-drug interaction studies have been conducted with paroxetine capsules. Paroxetine is a strong CYP2D6 inhibitor. Co-administration of paroxetine capsules can alter concentrations of other drugs that are metabolized by CYP2D6. Consider potential drug interactions prior to and during therapy ( 5.3 , 7.1 , 7.3 ). See Full Prescribing Information for a list of clinically significant drug interactions ( 7.1 , 7.2 , 7.3 ) 7.1 Potential for Paroxetine Capsules to Affect Other Drugs Paroxetine is a strong CYP2D6 inhibitor. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 [see Clinical Pharmacology (12.3)] . Table 2 contains examples of drugs with a metabolism that may be affected by co-administration with paroxetine capsules. Table 2 Effects of Paroxetine on Other Drugs Concomitant Drug Name Effect of Paroxetine on Other Drugs Clinical Recommendations Thioridazine Increased plasma concentrations of thioridazine Potential QTc prolongation Concomitant use of thioridazine and paroxetine capsules is contraindicated. Pimozide Increased plasma concentrations of pimozide. Potential QTc prolongation Concomitant use of pimozide and paroxetine capsules is contraindicated. Tamoxifen Reduced plasma concentrations of active tamoxifen metabolite Consider avoiding concomitant use of tamoxifen and paroxetine capsules. Tricyclic Antidepressants (TCA) (e.g., Desipramine) Increased plasma concentrations and elimination half-life Plasma TCA concentrations may need to be monitored and the dose of TCA may need to be reduced if a TCA is co-administered with paroxetine capsules. Monitor tolerability. Risperidone Increased plasma concentrations of risperidone A lower dosage of risperidone may be necessary (see the Full Prescribing Information for risperidone). Monitor tolerability. Atomoxetine Increased exposure of atomoxetine A lower dosage of atomoxetine may be necessary (see Full Prescribing Information for atomoxetine). Monitor tolerability. Drugs Highly Bound to Plasma Protein (e.g., Warfarin) Increased free plasma concentrations The dosage of warfarin may need to be reduced. Monitor tolerability and the International Normalized Ratio. Digoxin Decreased plasma concentrations of digoxin Dosage of digoxin may need to be increased. Monitor digoxin concentrations and clinical effect. Theophylline Increased plasma concentrations of theophylline Dosage of theophylline may need to be decreased. Monitor theophylline concentrations and tolerability. Use caution if co-administering paroxetine capsules with other drugs that are metabolized by CYP2D6, including nortriptyline, amitriptyline, imipramine, desipramine, fluoxetine, phenothiazines, risperidone, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide). 7.2 Potential for Other Drugs to Affect Paroxetine Capsules The metabolism and pharmacokinetics of paroxetine may be affected by the induction and inhibition of drug metabolizing enzymes such as CYP2D6. Table 3 contains a list of drugs that may affect the pharmacokinetics of paroxetine capsules when administered concomitantly [see Clinical Pharmacology (12.3)] . Table 3 Effects of Other Drugs on Paroxetine Concomitant Drug Name Effect of Concomitant Drug on Paroxetine Clinical Recommendations Phenobarbital Decreased paroxetine exposure No dose adjustment for paroxetine capsules. Monitor clinical effect of paroxetine capsules. Phenytoin Decreased paroxetine exposure Fosamprenavir/Ritonavir Decreased plasma concentration of paroxetine Cimetidine Increased plasma concentration of paroxetine Use caution if co-administering paroxetine capsules with other drugs that inhibit CYP2D6 (e.g., quinidine). 7.3 Other Potentially Significant Drug Interactions Monoamine Oxidase Inhibitors (MAOIs) Serious adverse reactions such as serotonin syndrome have been reported in patients receiving a concomitant SSRI and MAOI, in patients started on an SSRI who recently received an MAOI and in patients started on an MAOI who recently received an SSRI. Therefore, concomitant use of MAOIs with paroxetine capsules or use of paroxetine capsules and an MAOI within 14 days of each other is contraindicated [see Dosage and Administration (2.2), Contraindications (4.1) and Warnings and Precautions (5.2)] . Serotonergic Drugs If concomitant use of paroxetine capsules with other serotonergic drugs (e.g., other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. John’s Wort) is clinically warranted, consider the increased risk of serotonin syndrome and carefully observe the patient, particularly during treatment initiation [see Warnings and Precautions (5.2)] . An interaction between paroxetine and tryptophan may occur when they are co-administered. Adverse experiences, consisting primarily of headache, nausea, sweating, and dizziness, have been reported when tryptophan was administered to patients taking paroxetine. Consequently, concomitant use of paroxetine capsules with tryptophan is not recommended. Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin) Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs are co-administered with NSAIDs, aspirin, and warfarin or other drugs that affect coagulation. There may be a pharmacodynamic interaction between paroxetine and warfarin that causes an increased bleeding diathesis despite unaltered prothrombin time. Carefully monitor patients receiving warfarin therapy when paroxetine capsules is initiated or discontinued [see Warnings and Precautions (5.4)] .
Every paroxetine product we track (6)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Capsule | Generic | $3 | View → | |
| 2 | 66/100 | Prescription | Suspension | Generic | $3 | View → | |
| 3 | 66/100 | Prescription | Tablet | Generic | $3 | View → | |
| 4 | 66/100 | Prescription | Tablet | Generic | $3 | View → | |
| 5 | Not yet rated | Prescription | Capsule | Generic | $3 | View → | |
| 6 | Not yet rated | Prescription | Tablet | Generic | $3 | View → |
What paroxetine pills look like
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
How long does paroxetine take to work?
“It may take several weeks or longer before you feel the full benefit of paroxetine.” — MedlinePlus, U.S. National Library of Medicine.
What the NIH says about how quickly paroxetine worksParoxetine and breastfeeding
From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.
Full LactMed record for paroxetine: levels in milk, effects in breastfed infants, and the drugs it would consider insteadBecause of the low levels of paroxetine in breastmilk, amounts ingested by the infant are small and paroxetine has not been detected in the serum of most infants tested. Occasional mild side effects have been reported, especially in the infants of mothers who took paroxetine during the third trimester of pregnancy, but the contribution of the drug in breastmilk is not clear. . No adverse effects on development have been found in infants followed for up to 5 years of age. Most authoritative reviewers consider paroxetine one of the preferred antidepressants during breastfeeding. Monitor breastfed infants for excess sedation, agitation, irritability, poor feeding and poor weight gain
National Institute of Child Health and Human Development, record revised June 15, 2026. LactMed states its information is not a substitute for professional judgement.
What people report to the FDA about paroxetine
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 9,078 reports naming paroxetine, and the FDA flagged 84% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- fatigue714 reports
- nausea697 reports
- headache672 reports
- anxiety648 reports
- diarrhoea560 reports
- dizziness555 reports
- suicidal ideation547 reports
- depression536 reports
Read these as a signal, not a rate. A report does not mean paroxetine caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
How long paroxetine stays in your system
The elimination half-life of paroxetine is about 21 hours on average (the label reports a mean of approximately 21 hours, with 32% variability between people). This is the mean elimination half-life measured after 30 mg daily for 30 days; the label gives a single mean with 32% coefficient of variation rather than a range, so individual values vary widely. No active metabolite to worry about: the label states paroxetine's metabolites "have no more than 1/50 the potency of the parent compound at inhibiting serotonin uptake," so the parent drug's half-life is the one that matters. Paroxetine is not a prodrug. Paroxetine's kinetics are non-linear — it partly saturates the enzyme (CYP2D6) that clears it, so exposure rises more than proportionally with higher doses and with longer treatment, and the effective half-life can be longer than 21 hours at higher doses. The label does not print a separate half-life number for special populations (it presents them in a figure), but it does say drug exposure is higher and that "the recommended starting dosage and maximum dosage of paroxetine is reduced in elderly patients, patients with severe renal impairment, and patients with severe hepatic impairment" — so expect the drug to linger longer than 21 hours in those groups. This figure describes how long the drug itself is cleared from the body; it is not a drug-test detection window and not dosing guidance.
PAROXETINE tablet, film coated (Zydus Pharmaceuticals (USA) Inc.) — DailyMed, Section 12.3 Pharmacokinetics ↗Half-life is how long the body takes to clear half a dose. It is not the same as how long a drug test can detect it, and it varies with age, kidney and liver function.
Stopping paroxetine: withdrawal & how to come off
The label describes a Discontinuation Syndrome (Warnings and Precautions 5.7). Adverse reactions after stopping the drug, particularly after abrupt discontinuation, include nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances such as paresthesia (electric-shock sensations), tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. The label directs that the dosage be reduced gradually rather than stopped abruptly whenever possible, and that patients discuss any tapering regimen with their prescriber; it is a prescriber-managed taper. This discontinuation warning is not in the boxed warning (the boxed warning covers suicidal thoughts and behaviors).
This describes what the label says about stopping — not a schedule to follow on your own. Any change to paroxetineis your prescriber’s decision; stopping some medicines abruptly is dangerous.
Paroxetine tablets - DailyMed FDA label ↗Is paroxetine safe during pregnancy?
The label states a known risk
The label describes specific reported risks rather than reassurance. Based on published observational studies, first-trimester paroxetine use is associated with a less than 2-fold increase in cardiovascular malformations (meta-analyses report inconsistent overall findings but an increased risk for right ventricular outflow tract defects and atrial septal defect). It also cites risks of persistent pulmonary hypertension of the newborn (PPHN) and poor neonatal adaptation with SSRI exposure, complications in neonates exposed late in the third trimester (respiratory distress, feeding difficulty, jitteriness, seizures), and a less than 2-fold increased risk of postpartum hemorrhage when used in the month before delivery. The label states that for women who intend to become pregnant or who are in their first trimester, paroxetine should be initiated only after consideration of other available treatment options, and it also weighs the risk of untreated depression (relapse) in pregnancy. It does not tell patients to stop or start on their own — these decisions belong with the prescriber.
This is what paroxetine’s FDA label says — not a recommendation to take or stop it. In pregnancy, that decision is your prescriber’s; do not start or stop a medicine on your own.
Paroxetine tablets - DailyMed label (SPL) ↗Does paroxetine cause weight gain?
The label reports weight gain
Under Metabolic and Nutritional adverse reactions, the label lists weight gain as a Frequent adverse reaction and weight loss as infrequent. So the label does report weight gain (categorized as frequent, without a precise percentage), alongside less common weight loss.
Only what the FDA label reports — many drugs blamed for weight change online have no weight effect in their label, and we say so rather than repeat the folklore.
Paroxetine tablets - DailyMed label (SPL) ↗Related guides
Related calculators
Frequently asked questions
What is Brisdelle?
Brisdelle (Paroxetine Mesylate) is a serotonin reuptake inhibitor used to treat Feeding and Eating Disorders, Depressive Disorder, Obsessive-Compulsive Disorder, Phobic Disorders.
What kind of drug is paroxetine?
The FDA classifies paroxetine as a serotonin reuptake inhibitor. Selective serotonin reuptake inhibitors (SSRIs) block the transporter that pulls serotonin back into nerve cells, so more of this mood-related chemical stays in the gaps between neurons to keep signaling. They act mainly on serotonin, which tends to mean fewer side effects than older antidepressants. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.
Is paroxetine safe during pregnancy?
The label describes specific reported risks rather than reassurance. Based on published observational studies, first-trimester paroxetine use is associated with a less than 2-fold increase in cardiovascular malformations (meta-analyses report inconsistent overall findings but an increased risk for right ventricular outflow tract defects and atrial septal defect). It also cites risks of persistent pulmonary hypertension of the newborn (PPHN) and poor neonatal adaptation with SSRI exposure, complications in neonates exposed late in the third trimester (respiratory distress, feeding difficulty, jitteriness, seizures), and a less than 2-fold increased risk of postpartum hemorrhage when used in the month before delivery. The label states that for women who intend to become pregnant or who are in their first trimester, paroxetine should be initiated only after consideration of other available treatment options, and it also weighs the risk of untreated depression (relapse) in pregnancy. It does not tell patients to stop or start on their own — these decisions belong with the prescriber. This is what paroxetine's FDA label says; whether to use it in pregnancy is your prescriber's decision.
Does paroxetine cause weight gain?
Under Metabolic and Nutritional adverse reactions, the label lists weight gain as a Frequent adverse reaction and weight loss as infrequent. So the label does report weight gain (categorized as frequent, without a precise percentage), alongside less common weight loss.
What happens if you stop taking paroxetine?
The label describes a Discontinuation Syndrome (Warnings and Precautions 5.7). Adverse reactions after stopping the drug, particularly after abrupt discontinuation, include nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances such as paresthesia (electric-shock sensations), tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. The label directs that the dosage be reduced gradually rather than stopped abruptly whenever possible, and that patients discuss any tapering regimen with their prescriber; it is a prescriber-managed taper. This discontinuation warning is not in the boxed warning (the boxed warning covers suicidal thoughts and behaviors). Do not stop paroxetine on your own — any change is a prescriber-managed decision.
How long does paroxetine stay in your system?
The elimination half-life of paroxetine is about 21 hours on average (the label reports a mean of approximately 21 hours, with 32% variability between people) — that is how long the body takes to clear half of a dose. This is the mean elimination half-life measured after 30 mg daily for 30 days; the label gives a single mean with 32% coefficient of variation rather than a range, so individual values vary widely. No active metabolite to worry about: the label states paroxetine's metabolites "have no more than 1/50 the potency of the parent compound at inhibiting serotonin uptake," so the parent drug's half-life is the one that matters. Paroxetine is not a prodrug. Paroxetine's kinetics are non-linear — it partly saturates the enzyme (CYP2D6) that clears it, so exposure rises more than proportionally with higher doses and with longer treatment, and the effective half-life can be longer than 21 hours at higher doses. The label does not print a separate half-life number for special populations (it presents them in a figure), but it does say drug exposure is higher and that "the recommended starting dosage and maximum dosage of paroxetine is reduced in elderly patients, patients with severe renal impairment, and patients with severe hepatic impairment" — so expect the drug to linger longer than 21 hours in those groups. This figure describes how long the drug itself is cleared from the body; it is not a drug-test detection window and not dosing guidance. Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.
Can you take paroxetine with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run paroxetine against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is paroxetine sold under?
We track 6 paroxetine-containing products in the U.S.: Paroxetine Mesylate, Paroxetine Hydrochloride, Paxil, Paxil CR, Brisdelle and Pexeva. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does paroxetine come in?
Across the brands we track, paroxetine is currently marketed as capsule, suspension, tablet, extended release and tablet, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic paroxetine?
Yes. Our catalog lists 2 generic paroxetine products alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.
How long does it take for paroxetine to work?
It works gradually, not overnight. You may notice some early changes — sleep, appetite or energy — within the first 1 to 2 weeks, but the full effect on mood or anxiety usually takes about 4 to 6 weeks (sometimes up to 8). That delay is normal and is why prescribers ask you not to judge it too soon or stop early; give it time and stay in touch about side effects, and never stop abruptly.
What are the most common paroxetine side effects?
Nausea, drowsiness, dry mouth, sweating, constipation, dizziness, and sexual side effects such as reduced desire or delayed orgasm. Paroxetine is among the SSRIs most likely to cause sexual dysfunction, weight gain, and drowsiness. Early effects like nausea often ease over one to two weeks, while sexual side effects and weight changes tend to persist.
What serious paroxetine effects need urgent medical attention?
Paroxetine carries a boxed warning for increased suicidal thinking and behavior in people under 25, seek help immediately for worsening mood, agitation, or self-harm thoughts, especially early on. Get emergency care for serotonin syndrome (agitation, fever, fast heart rate, muscle rigidity or twitching, shivering), for a severe allergic reaction, or for signs of low sodium (severe headache, confusion, weakness, unsteadiness), which is more common in older adults.
Is paroxetine safe during pregnancy?
Paroxetine is generally avoided in pregnancy. Unlike most SSRIs, it has been linked to a higher risk of heart defects when taken in the first trimester, and it historically carried the FDA's pregnancy Category D designation (the letter categories have since been phased out of labeling in favor of a narrative risk summary). If you are pregnant or planning pregnancy, talk to your doctor before starting or stopping, do not stop suddenly on your own.
Why is stopping paroxetine harder than other antidepressants?
Paroxetine leaves the body quickly and has no long-acting active metabolite, so stopping it abruptly commonly causes discontinuation symptoms, dizziness, nausea, irritability, vivid dreams, and 'brain-zap' electric-shock sensations. These are uncomfortable but not usually dangerous. Always taper the dose gradually under your doctor's guidance rather than quitting cold.
Which paroxetine side effects are normal and which mean call the doctor?
Expected and usually temporary: mild nausea, sleepiness, dry mouth, and sweating, keep your prescriber updated but you generally don't stop. Contact your doctor promptly for easy bruising or bleeding (paroxetine can raise bleeding risk, especially with NSAIDs or blood thinners), a fast or irregular heartbeat, or confusion and weakness that could signal low sodium. Emergency signs are serotonin syndrome, a severe allergic reaction, or thoughts of self-harm.
Cite this page
- APA
- pharmaranks. (2026, July 24). Paroxetine: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/paroxetine
- MLA
- “Paroxetine: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/paroxetine.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for paroxetine on DailyMed (NIH) ↗ — including its boxed warning in full.